Vertex Pharmaceuticals grants stock to EVP Bozic

Vertex Pharmaceuticals executive vice president and CMO Carmen Bozic reported two stock award acquisitions of common stock on 01/22/2026.

Rhea-AI Filing Summary

Vertex Pharmaceuticals executive vice president and CMO Carmen Bozic reported two stock award acquisitions of common stock on 01/22/2026. The filings show grant/award acquisitions of 7,866 and 3,467 shares. Footnotes describe these as earned performance shares from performance stock unit awards granted on 02/01/2023 and 02/12/2025, after the management development and compensation committee certified performance-goal attainment on 01/22/2026, with vesting dates in February 2026. After these awards, she directly holds 44,002 Vertex shares.

Insider Trade Summary

Grant/Award: 11,333 shares

Grant/Award 2 txns

Insider Bozic Carmen

Role EVP and CMO

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	7,866	$0.00	$0.00
Grant/Award	Common Stock	3,467	$0.00	$0.00

Holdings After Transaction: Common Stock — 44,002 shares (Direct)

Footnotes (2)

1. F1. Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest on 02/13/2026.
2. F2. Represents earned performance shares with respect to a performance stock unit award granted on 02/12/2025 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest in installments beginning on 02/24/2026.

Key Figures

Stock award shares 1: 7,866 shares Stock award shares 2: 3,467 shares Direct holdings after transactions: 44,002 shares

3 metrics

Stock award shares 1 7,866 shares Grant/award acquisition of common stock on 2026-01-22 coded A

Stock award shares 2 3,467 shares Second grant/award acquisition of common stock on 2026-01-22 coded A

Direct holdings after transactions 44,002 shares Direct common stock held by Carmen Bozic after reported awards

Key Terms

performance stock unit award, performance-vesting requirements, management development and compensation committee

3 terms

performance stock unit award financial

"Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023"

performance-vesting requirements financial

"that contained performance-vesting requirements"

management development and compensation committee financial

"The issuer's management development and compensation committee certified as to the level of performance-goal attainment"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did VRTX executive Carmen Bozic report?

Carmen Bozic, EVP and CMO of Vertex (VRTX), reported two grant/award acquisitions of common stock on 01/22/2026, totaling awards of 7,866 and 3,467 shares. These transactions are coded as stock awards rather than open-market purchases or sales.

How many Vertex (VRTX) shares did Carmen Bozic receive in these awards?

On 01/22/2026, Carmen Bozic reported stock awards of 7,866 and 3,467 Vertex common shares. The awards are tied to performance stock unit programs and are reported as non-derivative grant/award acquisitions at no stated purchase price.

What is Carmen Bozic’s total direct shareholding in VRTX after these awards?

After the reported stock awards, Carmen Bozic directly holds 44,002 shares of Vertex common stock. This figure reflects her post-transaction balance and is reported as a direct ownership position in the canonical holdings summary.

Are the VRTX stock awards to Carmen Bozic tied to performance conditions?

Footnotes state that the reported awards represent earned performance shares from performance stock unit grants dated 02/01/2023 and 02/12/2025. The compensation committee certified performance-goal attainment on 01/22/2026, triggering future vesting of the related shares.

When will Carmen Bozic’s reported VRTX performance shares vest?

Footnotes explain that some earned performance shares will vest on 02/13/2026, while others will vest in installments beginning on 02/24/2026. These vesting dates apply to the performance stock unit awards tied to the certified performance goals.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/26/2026 - 04:22 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bozic Carmen

(Last) (First) (Middle)

C/O VERTEX PHARMACEUTICALS INCORPORATED

50 NORTHERN AVENUE

(Street)

BOSTON MA 02210

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VERTEX PHARMACEUTICALS INC / MA [ VRTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP and CMO

3. Date of Earliest Transaction (Month/Day/Year)
01/22/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/22/2026		A		7,866(1)	A	$0	40,535	D
Common Stock	01/22/2026		A		3,467(2)	A	$0	44,002	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest on 02/13/2026.

2. Represents earned performance shares with respect to a performance stock unit award granted on 02/12/2025 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest in installments beginning on 02/24/2026.

Remarks:

	/s/ Christiana Stevenson, Attorney-in-Fact	01/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.